Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...

Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional. It will separate teams that keep ...

The latest judgment follows another setback in its defence in October, when a California jury awarded an eye-watering $966 ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

At the same time, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has progressed, and the UK has ...

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.